ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,521 to 2,540 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Workers Who Perform Hand Hygiene on Entry Into Non-contact Precaution Room1,111 of 1,688

951 of 1,315

-6.5 points

-9.8 to -3.2

3,003NCT03119389

Direct Gloving Strategy: A Cluster-randomized Trial

Fondaparinux 2.5 mg vs Placebo: Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 7718 of 1,502

94 of 1,500

-5.1 points

-6.5 to -3.8

3,002NCT00443053

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Fondaparinux 2.5 mg vs Placebo: Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 4713 of 1,502

88 of 1,500

-5.0 points

-6.4 to -3.8

3,002NCT00443053

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

RPT Plus INH Regimen (Arm A) vs INH Regimen (Arm B): deaths from any cause21 of 1,496

27 of 1,504

-0.4 points

-1.3 to 0.5

3,000NCT01404312

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

RPT Plus INH Regimen (Arm A) vs INH Regimen (Arm B): serious adverse events40 of 1,496

68 of 1,504

-1.8 points

-3.2 to -0.5

3,000NCT01404312

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Endotracheal Intubation vs Laryngeal Tube (King): Return of Spontaneous Circulation (ROSC)361 of 1,495

420 of 1,505

-3.8 points

-6.9 to -0.6

3,000NCT02419573

Pragmatic Airway Resuscitation Trial

Endotracheal Intubation vs Laryngeal Tube (King): Number of Patients Alive at 72 Hours After Episode.230 of 1,495

275 of 1,505

-2.9 points

-5.6 to -0.2

3,000NCT02419573

Pragmatic Airway Resuscitation Trial

Endotracheal Intubation vs Laryngeal Tube (King): deaths from any cause1,265 of 1,495

1,230 of 1,505

2.9 points

0.2 to 5.6

3,000NCT02419573

Pragmatic Airway Resuscitation Trial

TAVR With Sentinel vs TAVR Without Sentinel: deaths from any cause11 of 1,501

7 of 1,499

0.3 points

-0.3 to 0.9

3,000NCT04149535

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

TAVR With Sentinel vs TAVR Without Sentinel: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First)34 of 1,501

43 of 1,499

-0.6 points

-1.8 to 0.5

3,000NCT04149535

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

TAVR With Sentinel vs TAVR Without Sentinel: serious adverse events285 of 1,501

315 of 1,499

-2.0 points

-4.9 to 0.8

3,000NCT04149535

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

Endotracheal Intubation vs Laryngeal Tube (King): Number of Patients Alive at Hospital Discharge121 of 1,495

163 of 1,504

-2.7 points

-4.8 to -0.6

2,999NCT02419573

Pragmatic Airway Resuscitation Trial

qHPV vs Placebo: serious adverse events38 of 1,499

43 of 1,498

-0.3 points

-1.5 to 0.8

2,997NCT00834106

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

Endotracheal Intubation vs Laryngeal Tube (King): Number of Patients With Favorable Neurologic Status on Hospital Discharge75 of 1,495

107 of 1,500

-2.1 points

-3.8 to -0.4

2,995NCT02419573

Pragmatic Airway Resuscitation Trial

MEDI8897 vs Placebo: deaths from any cause5 of 1,997

0 of 997

0.3 points

-0.2 to 0.6

2,994NCT03979313

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

MEDI8897 vs Placebo: serious adverse events149 of 1,997

83 of 997

-0.9 points

-3.0 to 1.1

2,994NCT03979313

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Standard RRT Initiation vs Accelerated RRT Initiation: serious adverse events8 of 1,489

15 of 1,503

-0.5 points

-1.2 to 0.2

2,992NCT02568722

Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)

Arm G - Metformin vs Arm G - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death54 of 1,443

49 of 1,548

0.6 points

-0.7 to 1.9

2,991NCT06042855

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Arm G - Metformin vs Arm G - Placebo: Number of Participants With Hospitalization or Death4 of 1,443

3 of 1,548

0.1 points

-0.3 to 0.5

2,991NCT06042855

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Arm G - Metformin vs Arm G - Placebo: serious adverse events7 of 1,443

3 of 1,548

0.3 points

-0.2 to 0.8

2,991NCT06042855

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=127"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=127

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03119389-9bb16884",
        "title": "Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Workers Who Perform Hand Hygiene on Entry Into Non-contact Precaution Room",
        "summary": "1111 of 1688 against 951 of 1315; risk difference -6.5 points, 95% interval -9.8 to -3.2; NCT03119389, Direct Gloving Strategy: A Cluster-randomized Trial",
        "record": "/library/comparisons/NCT03119389-9bb16884",
        "nct_id": "NCT03119389",
        "kind": "outcome",
        "participants": 3003,
        "risk_difference": {
          "value": -0.06501856089957292,
          "lower": -0.09787972235522363,
          "upper": -0.03169892261423946
        },
        "group_1": "1,111 of 1,688",
        "group_2": "951 of 1,315",
        "difference": "-6.5 points",
        "interval": "-9.8 to -3.2",
        "trial_title": "Direct Gloving Strategy: A Cluster-randomized Trial"
      },
      {
        "id": "NCT00443053-8a08e305",
        "title": "Fondaparinux 2.5 mg vs Placebo: Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77",
        "summary": "18 of 1502 against 94 of 1500; risk difference -5.1 points, 95% interval -6.5 to -3.8; NCT00443053, Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)",
        "record": "/library/comparisons/NCT00443053-8a08e305",
        "nct_id": "NCT00443053",
        "kind": "outcome",
        "participants": 3002,
        "risk_difference": {
          "value": -0.0506826453617399,
          "lower": -0.06479994659162429,
          "upper": -0.0375526696314879
        },
        "group_1": "18 of 1,502",
        "group_2": "94 of 1,500",
        "difference": "-5.1 points",
        "interval": "-6.5 to -3.8",
        "trial_title": "Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=128",
  "request_id": "ebPklYj7MlPfh4Re"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?